GlassScriptPhysician profile
Natalie Miles
NPI 1912616574
$2,240.85
in general payments reported to CMS, 2019-2025
24 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $14.90 · 2024: $1,210 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,786 · Education: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.98 |
| Education | $454.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $494.79 | 2024-2025 | Enhertu, Vanflyta, Injectafer |
| Astrazeneca Pharmaceuticals LP | $411.78 | 2024-2025 | Enhertu, Calquence, Imfinzi |
| Novartis Pharmaceuticals Corporation | $158.25 | 2024-2025 | |
| Lilly USA, LLC | $144.30 | 2024-2025 | Verzenio, Jaypirca |
| Astellas Pharma US INC | $135.24 | 2024-2025 | Xtandi, Padcev |
| Sobi, INC | $100.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.29 | 2024-2025 | |
| Gilead Sciences, INC. | $88.01 | 2024-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $86.97 | 2024-2025 | Krazati, Opdivo, Opdualag |
| Array Biopharma INC | $78.44 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Celgene Corporation | $69.92 | 2024-2025 | Reblozyl, Pomalyst, Opdivo |
| Merck Sharp & Dohme LLC | $68.30 | 2024-2025 | Keytruda, Lynparza |
| Incyte Corporation | $67.24 | 2024 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $39.44 | 2024-2025 | Fruzaqla, Ninlaro |
| Pfizer INC. | $32.71 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $31.58 | 2025 | Sancuso |
| Novocure INC. | $20.48 | 2025 | Optune Gio |
| Eisai INC. | $18.49 | 2024 | |
| Pharmacosmos Therapeutics INC. | $17.53 | 2025 | Monoferric |
| Aveo Pharmaceuticals, INC. | $17.47 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $16.79 | 2024 | Libtayo |
| Geron Corporation | $16.59 | 2025 | Rytelo |
| Janssen Biotech, INC. | $15.65 | 2024 | Erleada |
| Abbvie INC. | $15.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Miles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.